Bartholomew McKay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bartholomew McKay has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
David Cavallucci
Department of Hepatopancreaticobiliary Surgery Royal Brisbane Hospital Brisbane Queensland Australia
3 shared publicationsDaniel Kilburn
Department of Hepatopancreaticobiliary Surgery Royal Brisbane Hospital Brisbane Queensland Australia
2 shared publicationsAndrew Clouston
Envoi Specialist Pathologists, Brisbane, Queensland, Australia
1 shared publicationAnnabel L. Larder
D School of Medicine , Griffith University , Southport , Queensland , Australia
1 shared publicationAshu Jhamb
Department of Radiology St. Vincent’s Hospital Fitzroy Australia
1 shared publicationBavahuna Manoharan
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
1 shared publication
Latest Publications
- Open Access
- 23 June 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (9) , 1932-1939
To Stent or Not to Stent: Is It a Question? Routine Trans‐Cystic Stenting Does Not Reduce Biliary Anastomotic Strictures Post‐Liver Transplantation
Background: We aim to compare the incidence and risk factors for biliary anastomotic stricture (BAS) in patients undergoing orthotopic liver transplant (OLT) with and without transcystic externalised trans‐anastomotic biliary stenting. Methods: A retrospective analysis was performed of a prospective database focused on 836 cadaveric OLT. Primary outcome measures were the incidence of BAS and risk factors related to its development. Results: Duct‐to‐duct anastomosis was the most commonly performed biliary reconstruction (90.5%). Transcystic externalised trans‐anastomotic biliary stenting was performed in 420 patients (62.0%), being mostly used in patients having a duct‐to‐duct anastomosis (63.6%). BAS was seen in 222 (32.8%) patients, with a median time to diagnosis of 145.5 days ( IQR 50.3–370.5). BAS was higher in patients with a duct‐to‐duct reconstruction when compared to those having a bilio‐enteric reconstruction (34.3% vs. 18.7%, p = 0.02). The prevalence of BAS was not significantly different between patients who were stented and those who were not (34.5% vs. 30.0% respectively, p = 0.25). Multivariable analysis showed that older donor age, transplants performed earlier in the study period, higher MELD score, and type of biliary reconstruction (duct‐to‐duct) were independently associated with a higher risk of BAS . Conclusion: Transcystic externalised biliary anastomotic stenting is not associated with a reduced biliary stricture incidence in OLT.
- 23 June 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (9) , 1932-1939
Open AccessTo Stent or Not to Stent: Is It a Question? Routine Trans‐Cystic Stenting Does Not Reduce Biliary Anastomotic Strictures Post‐Liver Transplantation
Background: We aim to compare the incidence and risk factors for biliary anastomotic stricture (BAS) in patients undergoing orthotopic liver transplant (OLT) with and without transcystic externalised trans‐anastomotic biliary stenting. Methods: A retrospective analysis was performed of a prospective database focused on 836 cadaveric OLT. Primary outcome measures were the incidence of BAS and risk factors related to its development. Results: Duct‐to‐duct anastomosis was the most commonly performed biliary reconstruction (90.5%). Transcystic externalised trans‐anastomotic biliary stenting was performed in 420 patients (62.0%), being mostly used in patients having a duct‐to‐duct anastomosis (63.6%). BAS was seen in 222 (32.8%) patients, with a median time to diagnosis of 145.5 days ( IQR 50.3–370.5). BAS was higher in patients with a duct‐to‐duct reconstruction when compared to those having a bilio‐enteric reconstruction (34.3% vs. 18.7%, p = 0.02). The prevalence of BAS was not significantly different between patients who were stented and those who were not (34.5% vs. 30.0% respectively, p = 0.25). Multivariable analysis showed that older donor age, transplants performed earlier in the study period, higher MELD score, and type of biliary reconstruction (duct‐to‐duct) were independently associated with a higher risk of BAS . Conclusion: Transcystic externalised biliary anastomotic stenting is not associated with a reduced biliary stricture incidence in OLT.
- 7 May 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (6) , 1564-1572
Laparoscopic and Percutaneous Microwave Ablation for Hepatocellular Carcinoma—An Institutional Analysis of Complimentary Therapeutic Modalities
Introduction: Microwave ablation (MWA) is a locoregional thermoablative treatment for early HCC with equivalent outcomes to liver resection with reduced morbidity. Our study aimed to assess the oncological and perioperative outcomes of percutaneous and surgical MWA demonstrating their complementary utilization. Methods: All patients undergoing percutaneous (pMWA) and surgical (sMWA) MWA for HCC at St Vincent's Hospital in Melbourne, Australia between August 2011 and April 2023 were included. Results: 140 microwave ablations occurred in 107 patients with a median follow‐up of 37.1 months (range 2.4–105.9 months). There were 51 pMWA and 56 sMWA cases, of which 53 were undertaken laparoscopically. Surgical ablations had a higher BCLC stage, and due to more instances of multiplicity, sMWA delivered more ablations and energy per lesion. This was associated with longer procedural time (69.5 min vs. 45 min and p < 0.001) and postoperative length of stay (1 day vs. 2 days and p < 0.001). Clavien–Dindo III or more complications were no different between the groups ( p = 0.404). Local recurrence was significantly higher in the percutaneous group (31.4% vs. 10.7% and p = 0.016), and multivariate analysis demonstrated that technique was a predictor of local recurrence (sMWA HR 0.22, 95% CI 0.08–0.65, and p = 0.006). The median disease‐free survival was 3.0 years (95% CI 2.6–NS) for sMWA and 1.7 years (95% CI 1.5–3.7) for pMWA, but the difference was not significant ( p = 0.36). There were insufficient events to calculate median overall survival for each group; however, no differences were observed with an overall 5‐year survival estimate of 0.64 (95% CI 0.54–0.77 and p = 0.86). Conclusion: pMWA and sMWA are effective locoregional therapies for HCC. sMWA has the ability to deliver more energy per ablation with reduced local recurrence. However, overall survival is unaffected using the approach and both modalities should be used in a complimentary manner.
- 7 May 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (6) , 1564-1572
Laparoscopic and Percutaneous Microwave Ablation for Hepatocellular Carcinoma—An Institutional Analysis of Complimentary Therapeutic Modalities
Introduction: Microwave ablation (MWA) is a locoregional thermoablative treatment for early HCC with equivalent outcomes to liver resection with reduced morbidity. Our study aimed to assess the oncological and perioperative outcomes of percutaneous and surgical MWA demonstrating their complementary utilization. Methods: All patients undergoing percutaneous (pMWA) and surgical (sMWA) MWA for HCC at St Vincent's Hospital in Melbourne, Australia between August 2011 and April 2023 were included. Results: 140 microwave ablations occurred in 107 patients with a median follow‐up of 37.1 months (range 2.4–105.9 months). There were 51 pMWA and 56 sMWA cases, of which 53 were undertaken laparoscopically. Surgical ablations had a higher BCLC stage, and due to more instances of multiplicity, sMWA delivered more ablations and energy per lesion. This was associated with longer procedural time (69.5 min vs. 45 min and p < 0.001) and postoperative length of stay (1 day vs. 2 days and p < 0.001). Clavien–Dindo III or more complications were no different between the groups ( p = 0.404). Local recurrence was significantly higher in the percutaneous group (31.4% vs. 10.7% and p = 0.016), and multivariate analysis demonstrated that technique was a predictor of local recurrence (sMWA HR 0.22, 95% CI 0.08–0.65, and p = 0.006). The median disease‐free survival was 3.0 years (95% CI 2.6–NS) for sMWA and 1.7 years (95% CI 1.5–3.7) for pMWA, but the difference was not significant ( p = 0.36). There were insufficient events to calculate median overall survival for each group; however, no differences were observed with an overall 5‐year survival estimate of 0.64 (95% CI 0.54–0.77 and p = 0.86). Conclusion: pMWA and sMWA are effective locoregional therapies for HCC. sMWA has the ability to deliver more energy per ablation with reduced local recurrence. However, overall survival is unaffected using the approach and both modalities should be used in a complimentary manner.
- 14 November 2024
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (1-2) , 17-18
Patient‐reported outcomes: the last frontier in defining textbook outcomes in surgery
- 14 November 2024
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (1-2) , 17-18
Patient‐reported outcomes: the last frontier in defining textbook outcomes in surgery
- Open Access
- 26 March 2024
- Published by Wiley in Anz Journal of Surgery
- Vol. 94 (7-8) , 1247-1253
Safety and feasibility of instituting a robotic pancreas program in the Australian setting: a case series and narrative review
Background: Minimally invasive pancreatic resection has been gathering interest over the last decade due to the technical demands and high morbidity associated with these typically open procedures. We report our experience with robotic pancreatectomy within an Australian context.Methods: All patients undergoing robotic distal pancreatectomy (DP) and pancreaticoduodenectomy (PD) at two Australian tertiary academic hospitals between May 2014 and December 2020 were included.Results: Sixty‐two patients underwent robotic pancreatectomy during the study period. Thirty‐four patients with a median age of 68 years (range 42–84) were in the PD group whilst the DP group included 28 patients with a median age of 60 years (range 18–78). Thirteen patients (46.4%) in the DP group had spleen‐preserving procedures. There were 13 conversions (38.2%) in the PD group whilst 0 conversions occurred in the DP group. The Clavien‐Dindo grade ≥III complication rate was 26.4% and 17.9% in the PD and DP groups, respectively. Two deaths (5.9%) occurred within 90‐days in the PD group whilst none were observed in the DP group. The median length of hospital stay was 11.5 days (range 4–56) in the PD group and 6 days (range 2–22) in the DP group.Conclusion: Robotic pancreatectomy outcomes at our institution are comparable with international literature demonstrating it is both safe and feasible to perform. With improved access to this platform, robotic pancreas surgery may prove to be the turning point for patients with regards to post‐operative complications as more experience is obtained.
- 26 March 2024
- Published by Wiley in Anz Journal of Surgery
- Vol. 94 (7-8) , 1247-1253
Open AccessSafety and feasibility of instituting a robotic pancreas program in the Australian setting: a case series and narrative review
Background: Minimally invasive pancreatic resection has been gathering interest over the last decade due to the technical demands and high morbidity associated with these typically open procedures. We report our experience with robotic pancreatectomy within an Australian context.Methods: All patients undergoing robotic distal pancreatectomy (DP) and pancreaticoduodenectomy (PD) at two Australian tertiary academic hospitals between May 2014 and December 2020 were included.Results: Sixty‐two patients underwent robotic pancreatectomy during the study period. Thirty‐four patients with a median age of 68 years (range 42–84) were in the PD group whilst the DP group included 28 patients with a median age of 60 years (range 18–78). Thirteen patients (46.4%) in the DP group had spleen‐preserving procedures. There were 13 conversions (38.2%) in the PD group whilst 0 conversions occurred in the DP group. The Clavien‐Dindo grade ≥III complication rate was 26.4% and 17.9% in the PD and DP groups, respectively. Two deaths (5.9%) occurred within 90‐days in the PD group whilst none were observed in the DP group. The median length of hospital stay was 11.5 days (range 4–56) in the PD group and 6 days (range 2–22) in the DP group.Conclusion: Robotic pancreatectomy outcomes at our institution are comparable with international literature demonstrating it is both safe and feasible to perform. With improved access to this platform, robotic pancreas surgery may prove to be the turning point for patients with regards to post‐operative complications as more experience is obtained.
- 5 October 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (12) , 2897-2903
Robotic enucleation & uncinectomy of complex lesions of the proximal pancreas
BackgroundMalignant tumours within the proximal pancreas traditionally require pancreaticoduodenectomy (PD) for cure. For smaller lesions with borderline malignant potential the risk/benefit of PD becomes difficult to justify. Robotic approaches to these lesions allow for parenchymal preserving resection with reduced complication profile without oncological compromise.MethodsA review of a single surgeons prospectively collated database across two institutions of consecutive robotic enucleations or parenchyma preserving resections of the proximal pancreas was performed between July 2018 and October 2021. Standard demographic data, preoperative variables, intraoperative parameters, post-operative outcomes, morbidity and mortality were recorded.ResultsThirteen patients (8 female and 5 male) underwent robotic enucleation (EN) (8) and/or uncinectomy (UN) (5) in the proximal pancreas. Mean BMI was 32(kg/m2). Three patients (21%) underwent preoperative prophylactic pancreatic duct stenting. One patient required conversion to open. The median operative time in the EN group was 170 min (108-224 min) and the UN group was 160 min (110-204 min). The majority (8) of lesions were pNETs. Three lesions were IPMNs, with 1 solitary fibrous tumour and a serous cystic neoplasm (SCN) respectively. Median tumour size was 23 mm (11-58 mm) in the EN group, and 27 mm (17-38 mm) in the UN group. Ten of 13 patients had an R0 resection. There was no mortality in our series. Four (31%) patients across both groups developed clinically relevant POPF while none developed new endocrine or exocrine insufficiency. Average outpatient follow-up has been 6 months (1-18 months).ConclusionA robotic approach in proximal parenchymal preserving pancreatectomy is expanding, safe and feasible. Minimally invasive uncinectomy and enucleation of borderline malignant lesions of the proximal pancreas has become possible with the use of the robotic platform. With careful case selection, this allows a parenchymal preserving option to lesions traditionally necessitating morbid pancreaticoduodenectomy. We have proven that this is a developing, safe and effective technique.image
- 5 October 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (12) , 2897-2903
Robotic enucleation & uncinectomy of complex lesions of the proximal pancreas
BackgroundMalignant tumours within the proximal pancreas traditionally require pancreaticoduodenectomy (PD) for cure. For smaller lesions with borderline malignant potential the risk/benefit of PD becomes difficult to justify. Robotic approaches to these lesions allow for parenchymal preserving resection with reduced complication profile without oncological compromise.MethodsA review of a single surgeons prospectively collated database across two institutions of consecutive robotic enucleations or parenchyma preserving resections of the proximal pancreas was performed between July 2018 and October 2021. Standard demographic data, preoperative variables, intraoperative parameters, post-operative outcomes, morbidity and mortality were recorded.ResultsThirteen patients (8 female and 5 male) underwent robotic enucleation (EN) (8) and/or uncinectomy (UN) (5) in the proximal pancreas. Mean BMI was 32(kg/m2). Three patients (21%) underwent preoperative prophylactic pancreatic duct stenting. One patient required conversion to open. The median operative time in the EN group was 170 min (108-224 min) and the UN group was 160 min (110-204 min). The majority (8) of lesions were pNETs. Three lesions were IPMNs, with 1 solitary fibrous tumour and a serous cystic neoplasm (SCN) respectively. Median tumour size was 23 mm (11-58 mm) in the EN group, and 27 mm (17-38 mm) in the UN group. Ten of 13 patients had an R0 resection. There was no mortality in our series. Four (31%) patients across both groups developed clinically relevant POPF while none developed new endocrine or exocrine insufficiency. Average outpatient follow-up has been 6 months (1-18 months).ConclusionA robotic approach in proximal parenchymal preserving pancreatectomy is expanding, safe and feasible. Minimally invasive uncinectomy and enucleation of borderline malignant lesions of the proximal pancreas has become possible with the use of the robotic platform. With careful case selection, this allows a parenchymal preserving option to lesions traditionally necessitating morbid pancreaticoduodenectomy. We have proven that this is a developing, safe and effective technique.image
- 26 January 2020
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (6) , 1099-1103
Large size and haemorrhage are not contraindications to laparoscopic resection of hepatocellular adenoma
Background: Hepatocellular adenoma (HCA) is a hepatocyte derived neoplastic lesion with an increasing incidence and a strong association with oestrogen therapy. Laparoscopic resection has proven safe for small, non‐ruptured lesions whilst its use for large adenomas (≥10 cm) and cases of haemorrhage requires further investigation.Methods: All patients undergoing liver resection for HCA at the Royal Brisbane Hospital between January 2003 and April 2018 were analysed. Ethics approval was obtained.Results: Thirty‐three laparoscopic and three open resections were performed in 35 patients, all female, with a median age of 35 years (range 14–75). Nine laparoscopic resections were performed for large adenomas (≥10 cm) and 17 laparoscopic resections were performed for adenomas of intermediate size (5–9.9 cm). Only one conversion to open surgery was required for an intermediate sized tumour. Haemorrhage, either intratumoural, intraparenchymal or free intraperitoneal was the indication for resection in six of the 33 laparoscopic cases. Median operative time was 143 and 266 min for laparoscopically resected intermediate and large lesions, respectively. The median length of stay was 5 days (range 4–9) and no major complications were observed in the laparoscopic group. β‐catenin mutation was seen in four of nine large adenomas whereas the inflammatory subtype constituted 11 of 17 intermediate sized lesions.Conclusion: Laparoscopic surgery has been demonstrated to be safe for the resection of HCA in this group of patients. Importantly, haemorrhage and/or large size were not barriers to laparoscopic resection.
- 26 January 2020
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (6) , 1099-1103
Large size and haemorrhage are not contraindications to laparoscopic resection of hepatocellular adenoma
Background: Hepatocellular adenoma (HCA) is a hepatocyte derived neoplastic lesion with an increasing incidence and a strong association with oestrogen therapy. Laparoscopic resection has proven safe for small, non‐ruptured lesions whilst its use for large adenomas (≥10 cm) and cases of haemorrhage requires further investigation.Methods: All patients undergoing liver resection for HCA at the Royal Brisbane Hospital between January 2003 and April 2018 were analysed. Ethics approval was obtained.Results: Thirty‐three laparoscopic and three open resections were performed in 35 patients, all female, with a median age of 35 years (range 14–75). Nine laparoscopic resections were performed for large adenomas (≥10 cm) and 17 laparoscopic resections were performed for adenomas of intermediate size (5–9.9 cm). Only one conversion to open surgery was required for an intermediate sized tumour. Haemorrhage, either intratumoural, intraparenchymal or free intraperitoneal was the indication for resection in six of the 33 laparoscopic cases. Median operative time was 143 and 266 min for laparoscopically resected intermediate and large lesions, respectively. The median length of stay was 5 days (range 4–9) and no major complications were observed in the laparoscopic group. β‐catenin mutation was seen in four of nine large adenomas whereas the inflammatory subtype constituted 11 of 17 intermediate sized lesions.Conclusion: Laparoscopic surgery has been demonstrated to be safe for the resection of HCA in this group of patients. Importantly, haemorrhage and/or large size were not barriers to laparoscopic resection.
- 9 February 2019
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 71 (2) , 179-198
Pre-Operative vs. Peri-Operative Nutrition Supplementation in Hepatic Resection for Cancer: A Systematic Review
Despite improvements in safety of hepatic resection post-operative complications occur in up to a half of patients. A systematic review was undertaken to compare the effect of pre-operative and peri-operative nutritional supplementation on post-operative outcomes in patients undergoing hepatic resection for malignancy. Included studies were identified through a search of PubMed (1966 to November 2016), Embase (1947 to November 2016) and the Cochrane Library (1993 to November 2016). Eleven studies involving a total of 725 patients were included in this systematic review. BCAA supplementation in the pre-operative and peri-operative period was reported to reduce the overall complication rate by 26.9% (P = 0.01) in one cohort study while pre-operative immunonutrition was shown to reduce post-operative ascites by 25.4% (P =0.012) in another cohort study without affecting the overall complication rate. Four further studies on enteral supplementation failed to show a benefit with regards to post-operative complications. Post-operative mortality was unaffected by pre-operative and peri-operative BCAA. Both pre-operative and peri-operative nutritional supplementation have shown promising results regarding the post-operative course of patients undergoing hepatic resection for malignancy. No randomized controlled study exists directly comparing pre-operative and peri-operative nutrition and this needs to be focused on in future research.
- 9 February 2019
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 71 (2) , 179-198
Pre-Operative vs. Peri-Operative Nutrition Supplementation in Hepatic Resection for Cancer: A Systematic Review
Despite improvements in safety of hepatic resection post-operative complications occur in up to a half of patients. A systematic review was undertaken to compare the effect of pre-operative and peri-operative nutritional supplementation on post-operative outcomes in patients undergoing hepatic resection for malignancy. Included studies were identified through a search of PubMed (1966 to November 2016), Embase (1947 to November 2016) and the Cochrane Library (1993 to November 2016). Eleven studies involving a total of 725 patients were included in this systematic review. BCAA supplementation in the pre-operative and peri-operative period was reported to reduce the overall complication rate by 26.9% (P = 0.01) in one cohort study while pre-operative immunonutrition was shown to reduce post-operative ascites by 25.4% (P =0.012) in another cohort study without affecting the overall complication rate. Four further studies on enteral supplementation failed to show a benefit with regards to post-operative complications. Post-operative mortality was unaffected by pre-operative and peri-operative BCAA. Both pre-operative and peri-operative nutritional supplementation have shown promising results regarding the post-operative course of patients undergoing hepatic resection for malignancy. No randomized controlled study exists directly comparing pre-operative and peri-operative nutrition and this needs to be focused on in future research.
- 30 May 2016
- Published by Wiley in Journal of Surgical Oncology
- Vol. 114 (3) , 380-384
Intralesional PV‐10 for in‐transit melanoma—A single‐center experience
Background and Objectives: Patients with in‐transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco‐regional recurrence or in‐transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV‐10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities.Methods: Records were analyzed retrieving details of 19 patients treated with PV‐10 over a 4‐year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted.Results: Nineteen patients with in‐transit melanoma were treated with intralesional PV‐10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity.Conclusions: PV‐10 is an effective, durable, well‐tolerated treatment tool with an acceptable side effect profile for the management of unresectable in‐transit melanoma. J. Surg. Oncol. 2016;114:380–384.
- 30 May 2016
- Published by Wiley in Journal of Surgical Oncology
- Vol. 114 (3) , 380-384
Intralesional PV‐10 for in‐transit melanoma—A single‐center experience
Background and Objectives: Patients with in‐transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco‐regional recurrence or in‐transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV‐10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities.Methods: Records were analyzed retrieving details of 19 patients treated with PV‐10 over a 4‐year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted.Results: Nineteen patients with in‐transit melanoma were treated with intralesional PV‐10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity.Conclusions: PV‐10 is an effective, durable, well‐tolerated treatment tool with an acceptable side effect profile for the management of unresectable in‐transit melanoma. J. Surg. Oncol. 2016;114:380–384.
- 27 January 2016
- Published by Wiley in Internal Medicine Journal
- Vol. 46 (1) , 119-120
Acrokeratosis paraneoplastica (Bazex syndrome) associated with metastatic cutaneous squamous cell carcinoma
- 27 January 2016
- Published by Wiley in Internal Medicine Journal
- Vol. 46 (1) , 119-120
Acrokeratosis paraneoplastica (Bazex syndrome) associated with metastatic cutaneous squamous cell carcinoma